OncoPharm

By John BossaerScience

Favorites
38
Followers
Typical duration
14 min
per episode

Based on Podcast App listening data

OncoPharm episodes

May 22, 2025 Talking about cancer misinformation
If you've been struggling with how to talk to patients about ivermectin for cancer, then this podcast is for you.
1. Cancer misinformation on social media (Loeb, et al): https://doi.org/10.3322/caac.21857
2. Clinician communication with patients about cancer misinformation (Bylund, et al): https://doi.org/10.1200/OP.22.00526
16 min
May 22, 2025 Four New Drugs
Discussing recent FDA approvals of penpulimab, avutometenib, defactinib, and telisotuzumab vedotin.
13 min
May 08, 2025 Mg to Prevent Cisplatin Kidney Injury
A splashy large study and two small studies suggest IV Mg in pre-hydration fluids can decrease the risk of cisplatin kidney injury.
Gupta et al. JAMA Oncol (2025): doi:10.1001/jamaoncol.2025.0756
PRAGMATIC. ESMO Open (2022): https://doi.org/10.1016/j.esmoop.2021.100351
Yamamoto et al. Anticancer Res (2015): https://pubmed.ncbi.nlm.nih.gov/25862878/
16 min
May 01, 2025 TI-CH, Updates on dostarlimab, ventoclax, & zongertinib
This episode summarizes recent updates on:
Tumor infiltrating clonal hematopoiesis (TI-CH) and its apparent negative impact on solid tumors (https://www.nejm.org/doi/full/10.1056/NEJMoa2413361)
Updated dostarlimab data on MMRd use in rectal cancer and other solid tumors in the neoadjuvant (definitive?!?!) setting (https://www.nejm.org/doi/full/10.1056/NEJMoa2404512)
Phase 1 study of 7 + 3 + Venetoclax (https://doi.org/10.1182/blood.2024026700)
Zongertinib, a new HER2 TKI (https://www.nejm.org/doi/full/10.1056/NEJMoa2503704)
13 min
April 24, 2025 BRCA Reversion Mutations
BRCA revision mutations may explain some of the limited benefit seen in long-term follow-up studies with PARP inhibitors.
Bibliography:
1: BRCA reversion mutations predict resistance. https://doi.org/10.1158/2159-8290.CD-18-0715
2: SOLO3 Final OS Data. https://doi.org/10.1200/JCO.24.00933
3: Elucidating acquired PARP inhibitor resistance in advanced prostate cancer. https://doi.org/10.1016/j.ccell.2024.10.015
13 min
April 17, 2025 HOPA 25 Recap
Recapping HOPA 25 and Portland
*Great food (not discussed, the most excellent ETSU dinner at Arden)
*COCOON
*Pharmacists make everyone's job easier and keep patients out of the ED
*A few more tidbits too!
12 min
April 08, 2025 Expanded Approvals for Durvalumab, Lu 177 vt; Portland Preview
FDA expands approvals for durvalumab (bladder cancer) and Lutetium-177 vipivotide tetraxetan (pre-taxane in metastatic prostate cancer). Portland has places.
13 min
April 03, 2025 API-CAT & IMPROVE
We discuss reduced dose apixaban for months 6+ of treating cancer-associated VTE (API-CAT) and the impact (or lack thereof) of pausing BTK-inhibitors around vaccination (IMPROVE)
13 min
April 03, 2025 Topotecan
A Foundations of OncoPharm episode on Topotecan. (Originally to be released week of 3/27)
10 min
March 19, 2025 Keynote 811 Update
The updated Keynote 811 OS results convert an accelerated approval for pembrolizumab to a regular approval, albeit restricted by PD-L1 CPS status of 1 or higher.
13 min

About OncoPharm

From the publisher's feed

OncoPharm is a podcast dedicated to all things oncology pharmacy. Most episodes cover updates and recent publications concerning the use of medications in caring for patients with cancer. …